Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing agreement, Predictive Oncology recentl ...

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action.  POAI fully intends to protect its rights and defend against the claims asserted by ...

Core Insights - Predictive Oncology Inc. is leveraging over 150,000 live cell tumor samples and drug response data to enhance drug discovery and biomarker identification using AI and machine learning [1][12] - Regeneron Pharmaceuticals' acquisition of 23andMe for $256 million signifies a strategic shift towards data-driven drug discovery, emphasizing the value of genomic databases in therapeutic development [2][5] - 23andMe's extensive genomic dataset provides insights into disease progression and treatment efficacy, making it a valuable asset for precision drug development [3][4] Company Developments - Predictive Oncology has achieved a milestone in AI-enabled cancer drug discovery by developing predictive tumor response models for 21 previously untested molecules targeting common cancer types [7][8] - The company's AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to a specific drug compound, facilitating informed drug selection for testing [11][12] - The integration of AI and machine learning with real-world drug response data allows Predictive Oncology to expedite early-stage drug discovery and reduce risks in drug development [9][10] Industry Trends - The acquisition of 23andMe by Regeneron reflects a broader trend in the biopharma industry towards the convergence of AI, real-world data, and predictive analytics to enhance therapeutic outcomes [5][10] - The life sciences sector is undergoing a transformation where the integration of genomics and machine learning is becoming a foundational element in precision medicine [10]

Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in 2024 and projected to grow at a 19.4% CAGR through 2030, Predictive Oncology is poised to lead in precision oncology innovation PITTSBURGH, May 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following shareholder update recapping recent p ...

Financial Performance - The company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for Q1 2025, compared to a loss of $3.6 million in Q1 2024[1][11] - Revenue increased significantly from $4,858 in Q1 2024 to $110,310 in Q1 2025, primarily due to the completion of a tumor-specific 3D model[8][11] - Loss per common share from continuing operations improved to $0.32 in Q1 2025 from $0.88 in Q1 2024[8][11] Cash and Expenses - The company concluded Q1 2025 with $3.1 million in cash and cash equivalents, up from $611,822 as of December 31, 2024[8] - General and administrative expenses decreased by $497,464 to $1,828,200 in Q1 2025, compared to $2,325,664 in Q1 2024[8][11] - Net cash used in operating activities decreased to $985,840 in Q1 2025 from $2.7 million in Q1 2024, reflecting lower cash operating losses[8] Product Development and Partnerships - The company identified three promising compounds for repurposing in new cancer indications, including Afuresertib for breast cancer and Alisertib for colon cancer[4] - The company launched its ChemoFx drug response assay in Europe and expanded its availability in the United States, initially focusing on ovarian and gynecological cancers[3][4] - The company partnered with Tecan Group Ltd. to expand high-throughput drug screening capabilities using human tumor spheroids[4] Strategic Focus - The company completed the sale of Skyline Medical assets to DeRoyal Industries, which sharpened its focus on core AI-driven drug discovery capabilities[4]

PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science- driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in it ...

New indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens "This efficient screening approach on a small, curated cohort of abandoned drugs identified three compounds that warrant further exploration in tumor indications that have never been examined in this way," said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology. "The work that we have done successfully de ...

Financial Performance - For the year ended December 31, 2024, Predictive Oncology reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million[1] - The company recorded revenue of $1,623,817 in 2024, a slight decrease from $1,627,697 in 2023, primarily derived from its Eagan operating segment[9] - Basic and diluted net loss per common share from continuing operations decreased approximately 33% to $1.99 in 2024, compared to $2.99 in 2023[9] - Cash and cash equivalents decreased to $734,673 as of December 31, 2024, down from $8.7 million as of December 31, 2023[9] - General and administrative expenses decreased by $961,025 to $7,419,892 in 2024 from $8,380,917 in 2023, primarily due to lower employee-related expenses[9] Strategic Initiatives - The company announced an agreement to merge with Renovaro, which is expected to enhance its AI/ML drug discovery capabilities[2] - Predictive Oncology plans to launch its ChemoFx drug response assay in Europe, initially focusing on ovarian and other gynecological cancers[5] Revenue Growth - The Eagan operating segment contributed $1,539,005 in revenue for 2024, compared to $1,135,101 in 2023, indicating growth in this segment[9] Financing Activities - Predictive Oncology received more than $3.0 million in combined gross proceeds during the first three months of 2025 from various financing activities[5] Asset Management - The company completed the sale of assets related to its subsidiary, Skyline Medical Inc., to DeRoyal Industries, which is expected to reduce ongoing expenses significantly[5]

PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science- driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approxim ...